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INTRODUCTION:  
The  eye  as  a  portal  for  drug  delivery  is  generally used 
for local therapy against systemic therapy in o rder to  avoid   
the  risk  of  eye  damage  from  h igh  blood  concentrations  
of  the  drug,  which  is  not  intended.  The unique  anatomy,  
physiology  and  biochemistry  of  the eye  render  th is  organ  
impervious  to  foreign  substances, thus presenting a 
constant challenge to the formulator to circumvent  the  
protective  barriers  of  the  eye  without causing permanent 
tissue damage
1
. 
“Ophthalmic disorder” refers to physiologic abnormalit ies of 
the eye. They may involve the retina, the vitreous humor, 
lens, cornea, sclera  or other portions  of  the  eye,  or  
physiologic abnormalit ies  which  adversely  affect  the  eye,  
such  as  inadequate  tear  production.  Major ophthalmic  
disorders  affect  the  posterior  segment,  including  the  
retina  and  lens,  as  well  as  the anterior segment which 
includes the cornea, conjunctiva and sclera. Among the most 
important posterior  segment  disorders  are  macular  holes  
and  degeneration,  retinal  tears,  diabetic retinopathy,  
vitreoretinopathy  and  miscellaneous  disorders.  The most 
important disorder of the lens is cataract. The most important 
disorders of  the cornea  are  refractive disorders such as the 
sequelae of radial keratotomy, dry  eye, viral conjunctivitis, 
ulcerative conjunctivitis and wound healing (such as corneal 
epithelial wounds) and the consequences of Sjogren's 
syndrome
2
. 
A major problem being faced in ocular therapeutics is the 
attainment of an optimal concentration at the site of action. 
Poor bioavailability of drugs from ocular dosage forms is 
mainly due to the tear production, nonproductive absorption, 
transient residence time, and impermeability of corneal 
epithelium. In  addition to this, drugs that are hydrophobic or 
unstable at the pH comfortable in eye cannot be formulated as 
eye drops. Because of limitations of bioavailability pertaining 
to ocular route, there are many potent drugs, which still need 
to be studied for their therapeutic potential by topical ocular 
route. Novel drug delivery systems could be some effective 
means of exploring the potential of such drugs
3
. 
Ocuserts
4
 are defined as sterile preparations with a solid or 
semisolid consistency, whose size & shape are especially  
designed for ophthalmic application. Generally, all types of 
ocuserts consists of three components namely, a central drug 
reservoir in which the drug is incorporated in a polymer, rate 
controlling membrane which ensures the controlled release 
of medicament from the drug reservoir, and an outer annular 
ring meant for easy handling and proper insertion shown in 
figure no. 1. Ocuserts increases corneal contact time, 
prolongs duration of action, improves bioavailability, 
reduces the frequency of administration and thus achieves 
better patient compliance. Uniform ocular drug level 
eliminates systemic side effects and provides undisturbed 
sleep due to extended drug activity throughout the night. It is 
also possible to admin ister the drug to inflamed eye due to 
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sustained release of the medicament from ocusert. 
Furthermore, ocuserts are advantageous in saving time to the 
healthcare professionals. The efficacy of any ophthalmic 
drug
5
 depends on the rate and extent to which the drug 
reaches aqueous humour and ultimately to the interior 
segment or to target tissues for providing expected 
therapeutic response. 
The zero order kinetics
6
 characteristics a sustained release 
type of delivery system whereby the drug is held in a 
reservoir and is released into the tear film at constant rate to 
provide a constant concentration in the corner which  
provides greatly improved compliance  
 
 
Figure 1: Schemat ic diagram of ocular insert 
OCUS ERTS US ING IN VARIOUS EYE DIS EAS ES :  
1. Glaucoma
7
: Glaucoma refers to a group of eye conditions 
that lead to damage to the optic nerve. This nerve carries 
visual informat ion from the eye to the brain.In most cases, 
damage to the optic nerve is due to increased pressure in the 
eye, also known as intraocular pressure (IOP).  
Medication available but having side effects: Ophthalmic 
pilocarpine is used to treat glaucoma, a condition in which  
increased pressure in the eye can lead to gradual loss of 
vision. Pilocarp ine is in a class of medications called miot ics. 
It works by allowing excess fluid to drain from eye
8
.  
The amount of the drug administered in p ilocarp ine eye 
drops is substantially in excess of that needed for IOP 
control. The need to avoid this problem and the 
inconvenience of administering drops are leading to the 
development of a variety of alternative methods for drug 
delivery to the eye
9
. Pilocarpine needs to be administer four 
times a day which do not provide a constant therapeutic 
effect of the medication while leading the side effects of 
blurred or fluctuating vision and also not been tolerated by 
patients under the age of 40 and leeds to the fluctuation 
of intraocular pressure. 
Other Side Effects
10
: 
1. Prostaglandin Analogs: possible changes in eye color 
and eyelid skin, stinging, blurred v ision, eye redness, 
itching, burning. 
2. Beta Blockers: low b lood pressure, reduced pulse rate, 
fatigue, shortness of breath; rarely: reduced libido, 
depression. 
3. Alpha Agonists: burning or stinging, fatigue, headache, 
drowsiness, dry mouth and nose, relatively higher 
likelihood of allergic reaction. 
4. Carbonic Anhydrase Inhibitors: in eye drop form: 
stinging, burning, eye discomfort; in pill form: t ingling 
hands and feet, stomach upset, memory problems, 
depression, frequent urination. 
New advanced ocusert system  
Ocular inserts of Timolol maleate: Controlled release of 
timolo l maleate ocusert avoids the pulse-entry with which  
side-effects are associated. These systems can be based on 
any of several different mechanisms, and include both 
erodible and nonerodible matrices, wafers. Timolol maleate 
was the first β-blocker to be used as an anti-glaucoma agent 
and to date remains as the standard because none of the 
newer beta blockers were found to be more effective. 
Timolol maleate has the longest record of safety and efficacy 
to lower IOP and is administered via eye drops one or more 
times per day 
11
. They lengthen the extent of drug action by 
enhancement of corneal absorption. 
Pilocarpine ocusert: A matrix-dispersed pilocarpine soluble 
insert avoids some of the problems of administration of 
pilocarpine by drops. It has shown an effective lowering of 
the IOP with a duration of at least 24 hours.The insert is, in  
effect, a device for pro longing the contact time of the 
dispersed drug with the corneal tear film. It is therefore 
analogous to the use of agents which increase tear film 
viscosity, such as methylcellulose and polyvinyl alcohol
12
, 
without the disadvantage inherent in the removal of a drug-
soaked carrier such as the cotton pled-get. Since there is a 
limit to the effectiveness of increasing viscosity on drug 
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penetration, the duration of effect seen with these inserts can 
be attributed to prolonged release with the slow dissolution 
of the device
13
. 
2. Herpes Simplex Eye Disease: The most common herpes 
simplex eye disease caused is an infection of the cornea, 
which can potentially threaten sight. The infection varies in 
duration, severity and response to treatment, depending in 
part on which of several different strains of HSV type I 
caused the original infect ion. It can be considered a "cold 
sore" or "fever blister" of the eye14.Herpes simplex keratit is 
(HSK) remains a common cause of unilateral corneal 
disease
15
. 
Medication available but having side effects : Acyclovir, an  
antiviral is effective against human Herpes Simplex viruses, 
commercially availab le as a 3 % w/w eye ointment to be 
applied 5 times a day in the eye. The poor therapeutic 
response exhib ited by conventional ophthalmic ointments 
due to rapid precorneal elimination of the drug
16
. 
New advanced ocusert system 
 Acyclovir ocular inserts : They were prepared using solvent 
casting method said promising formulation would be able to 
offer benefits such as increase residence time, prolonged 
drug release, reduction in frequency of admin istration and 
thereby may help to improve the  patient compliance
17
. 
3. Eye Allergies : Eye allergies often are hereditary, and 
occur due to processes associated with other types of allergic 
responses. When an allergic reaction takes place, your eyes 
may be overreacting to a substance perceived as harmfu l, 
even though it may not be. These substances are called  
allergens
18
. 
For example, dust that is harmless to most people can cause 
excessive production of tears and mucus in eyes of overly 
sensitive, allergic indiv iduals. 
Medication available but having side effects: The 
disadvantage with Systane eye drops, use in eye allerg ies, 
especially with the gel formula, is that when first applied the 
eyes, people may experience a blurry vision for about 20 to 
30 seconds. It can also cause a little feeling of burning and 
stinging sensations around the eyes but not to the point that it 
will cause redness and further irritations to the eyes. 
Additionally, although it s a very rare case, at the initial 
application of the Systane eye drops, some people may  
experience pain in the eyes, changes in vision orientation and 
swelling and irritation.  
Blurred vision, headache, and increased tear production; 
swelling of the cornea and iris; temporary burning, irritation, 
pain, redness, stinging, or swelling of the eye are the side 
effects. 
New advanced ocusert system: Ketorolac tromethamine 
ocuserts were prepared using different polymers such as 
hydroxy propyl methylcellulose, ethyl cellu lose, 
methylcellu lose and polyvinyl pyrrolidone in different 
proportions
19
. 
4. Blepharitis
20
: An  infection  of  lid  tructures  (usually by  
staphylococcus  aureus)  with concomitant  seborrhoea,  
rosacea,  a  dry  eye  and abnormalities in lipid secretions . 
Medication available but having side effects : The poor 
bioavailability and therapeutic response exhib ited by 
Ofloxacin conventional ophthalmic solutions due to rapid 
pre-corneal elimination of the drug
21
. 
New advanced ocusert system: Ocular  inserts  were  
prepared  with  prolonged  release  of  drug  and  min imum  
swelling  within  cul-de-sac  using  Ofloxacin
21
.  
5.  Ocular Hypertension:  
The term ocular hypertension usually refers to any situation 
in which the pressure inside the eye, called intraocular 
pressure, is higher than normal. Eye pressure is measured in 
millimeters of mercury (mm Hg). Normal eye pressure 
ranges from 10-21 mm Hg. Ocular hypertension is an eye 
pressure of greater than 21 mm Hg
22
.  
Medication available but having side effects: Medicat ion 
for ocular hypertension having side effects shown in table 1. 
Table 1: Medication available but having side effects23: 
Medication Mechanism Dosage form Adverse effects 
Pilocarpine Muscarinic Agonist Eye Drops  
Timolol Β-Receptor Antagonist  Bradycardia 
Bronchoconstriction 
Acetazolamide Carbonic Anhydrase Inhibitor Systemic Administration Diuresis, Loss Of Appetite 
Tingling 
Neutropenia 
Clonidine Α2-Receptoe Agonist Eye Drops  
Ecothiopate Choline Esterase Inhibitor Eye Drops Muscle spasm 
Systemic effect 
Cartelol Β- Receptor Antagonist Eye Drops Bradycardia 
Bronchoconstriction 
Dorzolamide Carbonic Anhydrase Inhibitor Eye Drops Bitter taste 
Burning sensation 
Apraclonidine Α- 2 Agonist Eye Drops  
Lanatoprost Prostaglandin Analogue Eye Drops Ocular pigmentation 
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New advanced ocusert system 
Pilocarpine ocusert system for sustained control of ocular 
hypertension: A number of excellent drugs are availab le that 
are effective in reducing IOP. These drugs are typically  
applied as eye drops. However, patient adherence can be 
poor, thus reducing the clinical efficacy of the drugs. Several 
novel delivery systems designed to address the issue of 
adherence and to ensure consistent reduction of IOP are 
currently under development. A pilocarpine-containing, 
polymermembrane unit (Ocusert) was evaluated in 29 
patients with open-angle glaucoma.Their potential is 
dependent on developing suitable delivery systems that can 
provide the drugs in a sustained, local manner to the retina 
and optic nerve. Drug delivery systems have the potential to 
improve patient adherence, reduce side effects, increase 
efficacy, and ultimately, preserve sight for glaucoma 
patients
24
. 
6. Herpes Simplex Keratitis:  
Herpes Simplex kerat itis (HSK) is a viral infection that if left  
untreated can have devastating ocular consequences
25
. The 
keratit is caused by the herpes simplex virus (HSV) typically  
presents as a unilateral "red eye" with a variable degree of 
pain or ocular irritation. Photophobia and epiphora are 
common; however, vision may or may not be affected, 
depending upon the location and extent of the corneal lesion. 
You may see a vesicular skin rash and follicu lar 
conjunctivitis with the initial infect ion, but these are less 
common with recurrent HSV. A more common sign is 
secondary uveitis
26
.  
Medication available but having side effects
27
: Adverse 
events associated with the use of ganciclovir ophthalmic gel 
may include, but are not limited to, the following:  
1. Blurred Vision  
2. Eye Irritation 
3. Punctate Keratitis  
4. Conjunctival Hyperemia  
New advanced ocusert system 
Idoxuridine ocular insert therapy:use in treatment of 
herpes simplex kerati tis
28
: Therapy of acute herpes simplex 
keratit is in rabbits
 
with idoxuridine-releasing ocular inserts 
showed that an application
 
rate of 30µg/hr gave significantly  
better results than conventional treatment with idoxuridine 
drops and ointment while
 
exposing the eye to 40% less drug. 
Delivery rates lower than
 
this were equal or not as effective 
as drop and ointment therapy
 
and rates up to 100µg/hr did 
not produce significantly
 
better results than rates of 30µg/hr. 
Serial v iral cultures
 
demonstrated the persistence of virus 
beyond the period of clinical
 
resolution of disease in all 
treatment groups, indicating that
 
therapy should be continued 
longer than apparent resolution
 
of disease. 
7. Dry Eye Syndrome :  
Dry eye is a disorder of the tear film due to tear deficiency or 
excessive tear evaporation which causes damage to the 
interpalpebral ocular surface (i.e . e xposed eye surface) and is 
associated with symptoms of ocular discomfort. Th is 
definit ion of dry eyes was adopted by the National Eye 
Institute workshop on dry eyes
57
. 
The eye becomes dry either because there is not enough tears 
being produced or because there is abnormally high rate of 
evaporation of tears. 
New advanced ocusert system 
Hydroxypropyl  cellulose ophthalmic inserts for treatment 
of dry eye
29
: There are various treatment modalit ies for dry  
eye syndrome availab le to eye care professionals, which can 
be used as monotherapy or in combination. There is evidence 
to suggest that with proper use and adequate patient 
education, hydroxypropyl cellulose ophthalmic inserts are an 
effective and safe treatment choice for dry eye syndrome. 
Most patients showed significant improvement in ocular 
symptoms and clinical signs, and many patients continued 
using hydroxypropyl cellulose ophthalmic inserts for several 
years alone or in conjunction with other dry eye therapies. 
There was no significant worsening in symptoms or any 
major long-term side effects of the medication. The inserts 
may be particularly helpful in  patients who cannot tolerate 
preservatives or immunosuppressant drops, do not want to 
instill multip le artificial tears throughout the day, or still 
have an insufficient tear film despite other therapies. 
However, it is worth noting that several of the studies 
excluded patients with meibomian gland disease or 
blepharitis. It remains to be seen if the inserts help patients 
with evaporative aqueous tear loss due to meibomian gland 
dysfunction or blepharitis. One would think that both of 
these disease groups would benefit from using the inserts 
because there is often overlap of patients who also have dry 
eye syndrome. Nonetheless, hydroxypropyl cellulose 
ophthalmic inserts can be used effectively as monotherapy, 
or in conjunction with other therapies, and should be 
considered in the treatment of dry eye syndrome.  
8. Conjunctivitis:  
Conjunctivitis is the inflammat ion of the conjunctiva (the 
membrane that lines the eyelids and covers the exposed 
surface of the eyeball).Conjunctivitis can be caused 
by allerg ies, bacteria, v iruses, chemicals, or underly ing 
health conditions. The eyes are susceptible to infection 
because they are not sterile. They rely on lysozyme (an  
enzyme found in the tears) to destroy bacteria. Bacteria line 
the surface of the eyelids (all the way down into the shaft of 
the eyelashes), which makes the conjunctiva predisposed to 
germs and conjunctivitis
30
. 
Medication available but having side effects Moxifloxacin  
hydrochloride ophthalmic solution used. Serious side effects 
are not expected to occur during treatment with this 
medication. Some eye burning, stinging, irritation, itching, 
dryness, redness, tearing; or blurred vision may occur
31
. 
New advanced ocusert system  
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Polymeric Controlled Release Natamycin Ocular Inserts: 
Ocular drug delivery system for Natamycin; a polyene 
antibiotic is highly useful for the treatment of conjunctivitis 
and keratitis. Natamycin, a polyene antibiotic is highly useful 
for the treatment of fungal b lepharitis, conjunctivitis and 
keratit is. Natamycin when formulated as eye drops suffered 
the disadvantage of instillation of the dye drops for every 3-4 
h and hence maximized patient non compliance, leading to 
ineffective therapy
32
. 
9. Corneal Ulcers:  
A corneal ulcer is an erosion or open sore on the surface of 
the cornea. The cornea is the transparent area at the front part 
of the eye that serves as a window through which we see. It  
also refracts light and offers protection to other parts of the 
eye. If the cornea becomes inflamed due to infection or 
injury, an ulcer may develop. A corneal ulcer is a serious 
condition that must be treated promptly to avoid lasting 
vision problems
33
. 
Medication available but having side effects  Treatment for 
corneal ulcers needs to be aggressive, as some ulcers lead to 
vision loss and blindness. Treatment usually involves 
antibiotics as well as antiviral o r antifungal medications. 
Steroid eye drops may also be given to reduce inflammat ion 
but having side effects like White precip itate and ocular 
discomfort (stinging and burning may occur upon 
application). For e.g. In patients with corneal ulcer or 
frequent admin istration of the drug, white precipitates have 
been observed, which resolved spontaneously with continued 
application  The precipitate does not preclude continued use 
of CILOXAN Eye drops or CILOXAN Eye ointment, nor 
does it adversely affect the clinical course of the ulcer or the 
recovery process
34
. 
New advanced ocusert system  
Ocular inserts of Ofloxacin
35
: Ocular inserts of ofloxacin  
were prepared with objectives of reducing the frequency of 
administration, obtaining controlled release and greater 
therapeutic efficacy in the treatment of corneal ulcers. 
Ofloxacin ocular inserts were prepared to overcome the 
problem of the excret ion and low retention time into the eye. 
The prepared ocular inserts show the more retention time and 
less excretion through the eye secretions. The ocular inserts 
prepared were s mooth and passed all the evaluation tests.   
Formulat ions show a maximum cumulat ive percentage drug 
release of 91.27 % at the end of 24 hours. Ocuserts 
formulated also passed the test for sterility. They showed 
zero-order release of the drug in the in vitro and in vivo 
release studies. The drug in the films was found to be active 
against selected microorganis ms as was proved by microbial 
efficacy studies. A high correlation coefficient was found 
between in vitro and in vivo release rate studies. Shelf-life of 
the product was found to be more than one year
36
. 
Table number 2 : Research Work on Ocular Insert: 
 
S.No Drug  
Dosage 
form 
Category of 
drug 
Polymers / Bases  Reference  
1.  
Dexamethasone 
Ocular 
Insert    
Anti-
Inflammatory 
Cellu lose Acetate Phthalate, Eudragit  
RS. 100 And RL 100  
37 
 
2.  Pilocarpine Nit rate  
Ocular 
Insert  
Miotic Agent  Collagen 
38 
 
3.  Pilocarpine Nit rate  
Ocular 
Insert  
Miotic Agent  
Mixtures Of Sodium Salts Of 
Hyaluronic Acid  
39 
4.  Tropicamide  
Ocular 
Insert  
Mydriatic 
Agent 
Mixtures Of Sodium Salts Of 
Hyaluronic Acid 
39 
 
5.  Timolol Maleate  
Ocular 
Insert  
Anti-Glaucoma 
Agent 
Alkyl Monoesters Of Poly Viny l 
Methyl Ether-Maleic Anhydride 
(PVM - MA)  
40 
 
6.  
Ciprofloxacin 
Hydrochloride  
Ocular 
Insert  
Anti-Infective 
Agent  
Hydroxy Propyl Methyl Cellu lose, 
Methyl Cellu lose, Ethyl Ce llu lose 
And Polyvinyl Pyrrolidone  
41 
7.  
Ketorolac 
Tromethamine  
Ocular 
Inserts  
Anti-
Inflammatory  
Hydroxy Propyl Methyl Cellu lose, 
Polyvinyl Pyrrolidone, Methyl 
Cellu lose And Ethyl Cellu lose  
42 
8.  
Natamycin  
 
Ocular 
Inserts 
A Polyene 
Antibiotic Is 
Highly Useful 
For The 
Treatment Of 
Conjunctivitis 
And Keratitis 
Eudragit  L-100, Eudragit  S-100,  
Eudragit  RL-100,  Hydroxy  Propyl 
Methyl  Cellu lose  Phthalate  And 
Cellu lose  Acetate  Phthalate   
43 
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9.  Acyclovir 
Ocular 
Inserts 
An Antiviral Is 
Effective 
Against Human 
Herpes Simplex 
Viruses 
Hydroxypropylmethylcellulose, 
Polyvinylalcohol And Eudragit  
44 
10.  Levofloxacin  
Ocular 
Inserts 
Antibacterial 
Polyethylene Oxide , Sodium 
Alginate And Ethyl Cellulose 
45 
11.  Diclofenac Sodium 
Ocular 
Inserts 
 Non- steroidal, 
Anti-
Inflammatory  
Methyl Cellulose (MC), Sodium 
Carboxymethyl Cellulose (SCMC) 
Alone And In Combination.   
46 
12.  Fluconazole  
Ocular 
Inserts 
Antifungal 
Fluconazole Was Made Complex 
With Β-CD, And The Release Rate 
Was Controlled By HPMC K4M And 
Ethyl Cellu lose Polymers 
47 
13.  
Flurb iprofen 
Sodium 
Ocular 
Inserts 
Non- steroidal 
Anti-
Inflammatory 
Hydroxy Propyl Methyl Cellulose. 48 
14.  Azithromycin  
Ocular 
Inserts 
Antibacterial 
 Carbopol, And Hydroxypropyl 
Methylcellulose (HPMC) 
49 
15.  Dorsolamide HCL 
Ocular 
Inserts 
Carbonic 
Anhydrase 
Inhibitor  
Hydrophilic Po lymer PVP K 30 50 
16.  
Phenylephrine 
 
Ocular 
Inserts 
Mydriatic  
 
Gellan Gum 51 
17.  Pefloxacin  
Ocular 
Inserts 
Antibiotic 
Hydroxypropyl Methylcellu lose 
(HPMC) 
52 
18.  
Brimonid ine 
Tartarate 
Ocular 
Inserts 
Intraocular 
Pressure 
Lowering Agent 
Polyvinylpyrrolidone K-90 53 
19.  
Moxifloxacin 
Hydrochloride  
Ocular 
Inserts 
Antibacterials Gelat in 54 
20.  
Gatifloxacin 
Sesquehydrate 
Ocular 
Inserts 
Antibacterials 
Polyvinyl Alcohol And Polyvinyl 
Pyrrolidone. 
55 
21.  
 
Ofloxacin 
Ocular 
Inserts 
Antibacterials 
Hydroxy Propyl Methyl Cellu lose, 
Methyl Cellu lose, Poly Vinyl 
Pyrrolidone And Poly Vinyl Alcohol 
56 
 
CONCLUS ION 
The limitations of existing medical therapies for ocular 
disorders include low drug bioavailability, no specificity, 
side effects, and poor treatment adherence to therapy. These 
limitat ions may be overcome through the use of sustained-
release intraocular drug delivery systems. In the a rea of 
topical ocular administration, important efforts concern the 
design and the conception of new ophthalmic drug delivery  
systems able to prolong the residence time. The use of 
inserts, which are solid devices to be placed in the cul-the-
sac or on the cornea represents one of the possibilities to 
reach increased residence time. These solid ophthalmic 
devices present the advantage of avoiding a pulsed release 
due to multip le applications . 
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